Mounjaro (tirzepatide for T2DM) and Zepbound (tirzepatide for obesity) from Eli Lilly are growing at the fastest CAGR, driven by the dual GLP-1/GIP receptor agonist mechanism that has consistently demonstrated superior weight loss outcomes versus semaglutide in head-to-head clinical comparisons
What is the typical weight loss with AOD-9604
During sustained low to moderate exercise, fatty acid oxidation increases to become the predominant energy source to muscles [17]
"Todays action underscores Lillys commitment to improving access across the obesity care landscape
The mechanism of action includes several key effects: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood sugar levels Suppressing glucagon release , thereby reducing glucose production by the liver Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake Most GLP-1 medications are administered via subcutaneous injection , either once weekly (semaglutide, dulaglutide) or once daily (liraglutide), depending on the specific formulation
Chen H, Li J, Li N, Liu H, Tang J
